{"id":2448,"date":"2017-02-01T12:00:00","date_gmt":"2017-02-01T11:00:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2017\/hepatitis-b-alte-probleme-und-neue-aspekte-bei-der-praevention-und-therapie"},"modified":"2022-03-17T14:13:30","modified_gmt":"2022-03-17T13:13:30","slug":"hepatitis-b-alte-probleme-und-neue-aspekte-bei-der-praevention-und-therapie","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2017\/hepatitis-b-alte-probleme-und-neue-aspekte-bei-der-praevention-und-therapie","title":{"rendered":"Hepatitis B \u2013 alte Probleme und neue Aspekte bei der Pr\u00e4vention und Therapie"},"content":{"rendered":"<p>Zusammenfassung: Gegen die Infektion mit dem Hepatitis-B-Virus kann man sich durch gut vertr\u00e4gliche Impfungen sehr wirksam sch\u00fctzen. In Deutschland leben gesch\u00e4tzt 70.000 Menschen mit einer chronischen Hepatitis-B-Infektion. Wenn auch die Inzidenz der Hepatitis B in Deutschland zur\u00fcckgegangen ist, unterst\u00fctzten wir die Empfehlung der St\u00e4ndigen Impfkommission (STIKO), alle S\u00e4uglinge und Kleinkinder gegen Hepatitis B zu impfen, [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zusammenfassung: Gegen die Infektion mit dem Hepatitis-B-Virus kann man sich durch gut vertr\u00e4gliche Impfungen sehr wirksam sch\u00fctzen. In Deutschland leben gesch\u00e4tzt 70.000 Menschen mit einer chronischen Hepatitis-B-Infektion. Wenn auch die Inzidenz der Hepatitis B in Deutschland zur\u00fcckgegangen ist, unterst\u00fctzten wir die Empfehlung der St\u00e4ndigen Impfkommission (STIKO), alle S\u00e4uglinge und Kleinkinder gegen Hepatitis B zu impfen, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[3785,1446,2892,4538,2803,3566,1111,204,435,834,1455,404,431,3952,4571,2805,3137,3139,1454,2807,120,798,4824,3147,2963,2856,4823,974,803,802],"class_list":["post-2448","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-adefovirdipivoxil","tag-bosutinib","tag-daclatasvir","tag-dasabuvir","tag-dasatinib","tag-entecavir","tag-hepatitis-b","tag-hepatitis-c","tag-hepatozellulaeres-karzinom","tag-imatinib","tag-impfung","tag-lamivudin","tag-leberzellkarzinom","tag-leberzirrhose","tag-ledipasvir","tag-nilotinib","tag-ombitasvir","tag-paritaprevir","tag-pomalidomid","tag-ponatinib","tag-ritonavir","tag-rituximab","tag-simeprivir","tag-sofosbuvir","tag-telbivudin","tag-tenofoviralafenamid","tag-tenofovirdisoproxilfumarat","tag-thalidomid","tag-tyrosinkinase-hemmer","tag-tyrosinkinase-inhibitoren"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2448","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2448"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2448\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2448"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2448"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2448"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}